Clinical Trials Logo

Stage 0 Breast Cancer clinical trials

View clinical trials related to Stage 0 Breast Cancer.

Filter by:

NCT ID: NCT05318274 Recruiting - Clinical trials for Invasive Breast Cancer

Hypofractionated Radiation Therapy vs Standard Treatment in Breast Cancer.

Start date: April 26, 2021
Phase: N/A
Study type: Interventional

An explanatory study comparing complementary treatment to breast conservative surgery with radiation therapy DCIS, T1-T2 N0 M0 (AJCC v8) 1 week schedule vs 3.1 weeks standard schedule, in order to determine the equivalence of local tumor control, survival, acute and chronic toxicity. Shorter curse of radiation therapy may lead to similar local control of tumor cells and lower rates of toxicity than 3.1 standard treatment.

NCT ID: NCT04849871 Recruiting - Breast Cancer Clinical Trials

Single Fraction Accelerated Partial Breast Irradiation vs. Five Fraction Accelerated Partial Breast Irradiation for Low-risk Stage 0 and I Breast Carcinoma

BreaStBRT
Start date: August 12, 2021
Phase: N/A
Study type: Interventional

This study will evaluate the local control, complication rates, cosmetic results, and quality of life between patients treated with a single fraction vs. five fractions of accelerated partial breast irradiation (S_APBI vs. F_APBI) when used as the sole method of radiation therapy.

NCT ID: NCT03345420 Active, not recruiting - Clinical trials for Stage II Breast Cancer

Hypofractionated Radiation Therapy in Treating Patients With Stage 0-IIB Breast Cancer

NOVEMBER
Start date: December 12, 2017
Phase: Phase 2
Study type: Interventional

This phase II trial studies how well hypofractionated radiation therapy works in treating patients with stage 0-IIB breast cancer. Hypofractionated radiation therapy delivers higher doses of radiation therapy over a shorter period of time and may kill more tumor cells and have fewer side effects.

NCT ID: NCT03238703 Withdrawn - Clinical trials for Invasive Breast Carcinoma

Endocrine Therapy in Treating Patients With HER2 Negative, Low Risk Breast Cancer

Start date: September 1, 2018
Phase: Phase 4
Study type: Interventional

This pilot clinical trial studies how well endocrine therapy works in treating patients with HER2 negative, low risk breast cancer. Estrogen can cause the growth of breast cancer cells. Endocrine therapies such as aromatase inhibitors and selective estrogen receptor modulators may lessen the amount of estrogen made by the body.

NCT ID: NCT03139435 Completed - Clinical trials for Stage IV Breast Cancer

Ultrasound in Detecting Taxane-Induced Neuropathy in Patients With Breast Cancer

Start date: May 11, 2017
Phase: N/A
Study type: Interventional

This pilot clinical trial studies how well ultrasound works in detecting taxane-induced neuropathy in patients with breast cancer. Ultrasound may work better in diagnosing and detecting neuropathy in breast cancer patients treated with the chemotherapy drug called a taxane.

NCT ID: NCT03061175 Completed - Clinical trials for Stage IIIA Breast Cancer

Web-Based Decision Aid in Improving Informed Decisions in Patients With Stage 0-IIIA Breast Cancer Considering Contralateral Prophylactic Mastectomy

Start date: September 24, 2015
Phase: N/A
Study type: Interventional

This pilot randomized clinical trial studies how well a web-based decision aid works in improving informed decisions in patients with stage 0-IIIA breast cancer considering contralateral prophylactic mastectomy (CPM). A web-based decision aid (DA) may help doctors determine how patients make decisions about whether or not to have contralateral prophylactic mastectomy.

NCT ID: NCT03050463 Completed - Clinical trials for Stage IIIA Breast Cancer

Functional Magnetic Resonance Imaging in Assessing Affect Reactivity and Regulation in Patients With Stage 0-III Breast Cancer

Start date: August 2016
Phase:
Study type: Observational

The investigators hope to gain a better understanding of the influence of affect reactivity and regulation on the decision of newly diagnosed breast cancer patients to choose bilateral mastectomy. The information gained can help develop an intervention to enable management of cancer-related anxiety by non-surgical means.

NCT ID: NCT03039140 Completed - Clinical trials for Stage IIIA Breast Cancer

Cardiac Rehabilitation Program in Improving Cardiorespiratory Fitness in Stage 0-III Breast Cancer Survivors

Start date: May 14, 2015
Phase: N/A
Study type: Interventional

This clinical trial studies a cardiac rehabilitation program in improving cardiorespiratory fitness in stage 0-III breast cancer survivors. Cardiovascular disease is the leading cause of death of women in both the general population and the breast cancer survivor population. There are many risk factors common to both heart disease and breast cancer development, including physical inactivity. A cardiac rehabilitation program may help improve cardiorespiratory fitness, reduce cardiovascular disease risk factors, and improve quality of life among breast cancer survivors.

NCT ID: NCT03025139 Active, not recruiting - Clinical trials for Stage IIIA Breast Cancer

Mindfulness Meditation or Survivorship Education in Improving Behavioral Symptoms in Younger Stage 0-III Breast Cancer Survivors (Pathways to Wellness)

PTW
Start date: February 20, 2017
Phase: N/A
Study type: Interventional

This randomized phase III trial studies how well mindfulness meditation or survivorship education work in improving behavioral symptoms in younger stage 0-III breast cancer survivors. Behavioral interventions, such as mindfulness meditation, use techniques to help patients change the way they react to environmental triggers that may cause a negative reaction. Survivorship education after treatment may reduce stress and improve the well-being and quality of life of patients with breast cancer. Mindfulness meditation or survivorship education may help improve the health behaviors of younger breast cancer survivors.

NCT ID: NCT02728596 Completed - Clinical trials for Stage IV Breast Cancer

S1415CD, Trial Assessing CSF Prescribing Effectiveness and Risk (TrACER)

TrACER
Start date: October 7, 2016
Phase: N/A
Study type: Interventional

This randomized clinical trial studies prophylactic colony stimulating factor management in patients with breast, colorectal or non-small cell lung cancer receiving chemotherapy and with risk of developing febrile neutropenia. Patients receiving chemotherapy may develop febrile neutropenia. Febrile neutropenia is a condition that involves fever and a low number of neutrophils (a type of white blood cell) in the blood. Febrile neutropenia increases the risk of infection. Colony stimulating factors are medications sometimes given to patients receiving chemotherapy to prevent febrile neutropenia. Colony stimulating factors are given to patients based on guidelines. Some clinics have an automated system that helps doctors decide when to prescribe them when there is a high risk of developing febrile neutropenia. Gathering information about the use of an automated system to prescribe prophylactic colony stimulating factor may help doctors use colony stimulating factor when it is needed.